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Introduction 
 
VACTERL association (OMIM#192350) is a rare, 
non-random co-occurrence of at least three of the 
following congenital malformations: vertebral defects 
(V), anorectal anomalies (A), cardiac defects (C), 
trachea-oesophageal fistula with or without 
oesophageal atresia (TE), renal anomalies (R) and 
limbs defects (L) [1]. The prevalence of VACTERL 
association among infants ranges from 1/10,000 to 
1/40,000 births with a male predominance [1]. Until 
now, the aetiology of the VACTERL is not fully 
understood thus making the diagnosis rather 
challenging. Currently, VACTERL is diagnosed based 
on clinical manifestations of the above malformations 
after exclusion of other syndromes [2]. Heterogeneous 
phenotypes of VACTERL could lead to overlapping 
defects with other diseases such as CHARGE, 
Feingold, McKusick-Kaufman, Pallister-Jall, Alagille, 
and Fanconi Anemia [1]. Although the clinical 
diagnosis of VACTERL is mostly definite, molecular 
diagnosis may assist the clinicians for disease 
prognostication and management. Currently, genetic 
counselling for families with VACTERL is based on 
the existing knowledge; however it is still 
unsatisfactory. Exploratory genetic and environmental 
studies will allow for personalised treatment to 
improve the survival rates of children with multiple 
congenital anomalies. 
 
Previous studies have shown that about 80% of 
VACTERL association cases are due to sporadic 
mutations during embryogenesis, whereas 20% of 
them are due to genetic inheritance via autosomal 
recessive or X-linked recessive traits [3]. Several 
genetic mutations have been identified in VACTERL 
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VACTERL association is a rare genetic disorder involving at least three of the following congenital 
malformations: vertebral defects (V), anal atresia (A), cardiac defects (C), trachea-oesophageal fistula with 
or without oesophageal atresia (TE), renal anomalies (R) and limb abnormalities (L). Until now, the 
aetiology of VACTERL association is unknown, particularly at the molecular level. Here, we performed 
whole exome sequencing (WES) of an infant with VACTERL association. The patient was delivered 
prematurely at 30 weeks and had 4/6 of the VACTERL malformations. Trio-WES analysis was performed 
using Torrent Suite and ANNOVAR. Polymorphisms with an allele frequency of >0.01 were excluded, and 
the remaining variants were filtered based on de novo mutations, autosomal recessive, X-linked and di-genic 
inheritance traits. In this patient, no homozygous, compound heterozygous or X-linked mutations was 
associated with VACTERL. However, we identified two heterozygous mutations; KIF27 
(ENST00000297814: c.3004A> C:p.N1002H) and GNAS (ENST00000371098: c.205C>A:p.H69N) genes that 
were inherited from her father and mother respectively. A de novo, IFT140 gene mutation 
(ENST00000426508: c.683C>G:p.S228C) was also identified in this patient. The VACTERL phenotype in 
this patient may due to heterozygous mutations affecting KIF27 and GNAS genes, inherited via autosomal 
recessive trait. In addition, the IFT140 gene mutation may also be involved. These genes are known to be 
directly or non-directly involved in the sonic hedgehog signalling that is known to be implicated in 
VACTERL. This is the first report of these genetic mutations in association with VACTERL. 
 
 




association or VACTERL-like association including 
HOXD13 [4], ZIC3 (X-linked) [5], PTEN [6], FANCB 
[7], FOXF1 [8] PCSK5 [9] and TRAP1 [10] genes. In 
the experimental mouse model of VACTERL, the 
sonic hedgehog (SHH) signalling pathway has been 
identified to be implicated in VACTERL 
pathogenesis, particularly with the loss of function in 
SHH and GLI genes [11]. Similarly, the intraflagellar 
transport (IFT) pathway has also been linked to the 
VACTERL pathogenesis [12], as the IFT pathway is 
needed for mammalian SHH signal transduction [13]. 
In addition, mitochondrial dysfunction including 
complex IV deficiency and A3243G mitochondrial 
DNA mutation has also been associated with 
VACTERL association [14], thus suggesting the 
heterogeneity in VACTERL causative candidate 
genes. Therefore, determination of these genetic 
factors and their consequences are important to add 
further information on the aetiology and possibly 
identify the molecular mechanisms involved in the 
pathogenesis of the VACTERL association.  
 
Previously, genetic screening studies have been 
limited to the identification of candidate genes only. 
With the advent of next-generation sequencing, 
screening of the whole genome can be done in a more 
cost-effective manner. One such technique is whole 
exome sequencing (WES), which is a powerful tool in 
the investigation of disease-causing-mutations at the 
genome-wide level and has uncovered novel 
mutations associated with various rare diseases 
[15]. Here, we report the genetic data of an infant girl 
who was diagnosed with VACTERL association via 
the trio genetic analysis using the whole exome 
sequencing (WES) platform. We aimed to add to the 
knowledge of the pathogenesis of VACTERL 
association.. 
 
Materials and methods 
 
Subject and clinical findings 
 
An infant girl was delivered prematurely (Gestation 
age = 30 weeks) by emergency Caesarean section due 
to breech presentation and multiple congenital 
anomalies, with a birth weight of 1.48 kg. The 
patient’s family history was without known inborn 
abnormalities. She was the first child of a non-
consanguineous marriage between two phenotypically 
normal individuals. Her mother and father were 33 and 
39 years old respectively when she was born. Her 
mother was diagnosed with Type 2 Diabetes Mellitus 
when she was 25 years old. At birth, the patient was 
diagnosed with VACTERL association. Anomalies 
observed were; 1) sacral agenesis with no presence of 
spina bifilda, 2) high type of anorectal anomaly, 3) 
situs ambiguous with single ventricle, unrestricted 
pulmonary blood flow and patent ductus arteriosus 
(PDA) and 4) right thumb syndactyly, rocker bottom 
feet with overlapping toes and right congenital talipes 
equinovarus (CTEV). There were no 
tracheoesophageal fistula, oesophageal atresia or renal 
anomalies. At 2 days of life, the patient underwent a 
left transverse loop colostomy for her anorectal 
anomaly. When the patient was treated at the neonatal 
intensive care unit (NICU), she developed heart 
failure, and was treated with frusemide, 
spironolactone and captopril. She also had sepsis and 
was treated with antibiotics but later developed 
disseminated intravascular coagulation. The patient 
died at 27 days of life due to the severe sepsis with 




Blood was sampled from the patient to culture the 
lymphocytes according to standard protocol. Giemsa-
banded chromosomes from 20 metaphases were 
performed. Further investigation using fluorescence in 
situ hybridisation (FISH) was performed using probes 
for 22q11.2 (N25 and TUPLE1, 
DiGeorge/velocardiofacial syndrome critical region) 
and chromosomes 13 and 18 (Vysis Abbott Molecular 
Inc., USA). 
 
DNA isolation, library construction, and exome 
sequencing 
 
Following genetic counselling, the parents provided 
written informed consent for exome sequencing. 
About 3ml of peripheral blood was taken from the 
patient and both of her parents to extract the genomic 
DNA using salt extraction method. The DNA quality 
and purity were assessed using agarose gel 
electrophoresis and NanoDrop unit (Thermo Fisher 
Scientific, USA) respectively. DNA concentration was 
measured using a Qubit dsDNA BR Assay Kit 
(Thermo Fisher Scientific, USA). DNA libraries were 
prepared using an Ion AmpliSeq™ Exome RDY Kit 
(Thermo Fisher Scientific, USA) according to the 
manufacturer’s instructions. Briefly, 100 ng of 
genomic DNA was mixed with the 5X Ion 
AmpliSeq™ HiFi Mix and loaded into the Ion 
AmpliSeq™ Exome RDY plate for library 
amplification and barcoding according to 
manufacturer’s recommendation. Amplified libraries 
were confirmed for their quality and quantity using the 
High Sensitivity DNA kit (Agilent Technologies, 
USA) on Bioanalyzer (Agilent Technologies, USA). 
The libraries were then sequenced using the Ion 
Proton™ System (Thermo Fisher Scientific, USA) 
according to the manufacturer’s recommendations. 





Bioinformatics data analysis 
 
Read mapping and variant calling was performed 
using Ion TorrentSuite™ v5.0.4 software (Thermo 
Fisher Scientific, USA) using the default parameters. 
The reads were aligned to the human reference 
genome hg19, followed by variant calling using 
TorrentSuite™ Variant Caller v5.0.13. Next, variants 
with single nucleotide polymorphism (SNP) quality ≤ 
30 were filtered out using SnpSift [16] followed by 
annotation with ANNOVAR [17]. Only non-
synonymous variants in coding regions (exonic, 
splicing) with read depth > 5X were retained for 
further analysis. To identify the disease-causing 
mutations, polymorphisms with the allele frequencies 
> 0.01 reported in the 1000 Genomes Project, NHLBI 
Exome Sequencing Project (ESP) Exome Variant 
Server, Exome Aggregation Consortium (ExAC), 
Complete Genomics (cg69) and maximum population 
frequency were filtered out. Subsequently, the putative 
disease-causing mutations were identified by filtering 
based on de novo, autosomal recessive, X-linked 
recessive and di-genic inheritance traits. Variants that 
fulfilled the above criteria were manually inspected 
using Integrative Genomics Viewer (IGV) to filter out 
false positive variants [18, 19] and further validated 
with exome data of 50 healthy controls to confirm the 
presence of the mutations. The effects of the 
confirmed variants were predicted using SIFT [20], 
PolyPhen-2[21], Mutation Taster [22], FATHMM 
[23], CADD [24], PROVEAN [25], and DANN [26]. 
Candidate mutations which were predicted to be 
deleterious by one of the above tools were further 
studied through searching literature databases. 
Identification of the implicated pathway was 
performed using the pathway enrichment analysis 
based on the Kyoto Encyclopaedia of Genes and 
Genomes (KEGG) database [27] and also other 
pathway databases including PANTHER [28] and 






For the patient, giemsa-banded chromosomes from 20 
metaphases showed a normal female karyotype (46, 
XX). Analysis of 200 nuclei and metaphases showed 
no deletion of the N25 and TUPLE1 regions and no 











Variants detected via whole exome sequencing 
(WES) 
 
About 39 million reads were mapped to the hg19 
genome base for all the samples, with an average of 
83.98% of bases covered at > 20X coverage (Table 1). 
The lowest mean depth of coverage was 97.1X and the 
highest was 127.9X (Table 1). The average uniformity 
across the samples was 82.09% (Table 1). 
 
Table 1. Descriptive findings of the summary for whole 
exome sequencing of the patient and her unaffected 
parents. 
  
Summary of the whole exome sequencing parameters for the 
patient and her unaffected parents. 
 
Parameter Patient Father Mother 
Mapped reads 
 
39114273 45956362 34359247 
Percentage of on-target 
(%) 
 
95.90 92.48 92.98 
Mean depth coverage 
 
116.7X 127.9X 97.1X 
20X coverage (%) 
 
92.12 83.79 76.03 
Uniformity (%) 90.45 79.16 76.65 
No. of total variants 
identified 
 
41500 41802 37602 
No. of total variants 
with quality score ≥ 30 
31035 33652 29303 
 
Figure 1: (A) Family pedigree of the patient. Open symbols, 
unaffected parents; closed symbol, affected patient. Normal 
fluorescence in-situ hybridisation (FISH) results of locus 
specific (LSI) probes for (B) chromosome 13 (orange) and 
18 (green), and chromosome 21, (C) TUPLE1 (orange) and 
(D) N25 (orange) with arylsulfatase A (green, control) in 
affected patient. 
 




Heritable mutations in VACTERL association 
 
To identify the heritable mutations associated with 
VACTERL association, the list of mutations was 
filtered based on autosomal recessive and X-linked 
recessive traits. Table 2 shows the mutations identified 
based on di-genic inheritance, autosomal recessive and 
de-novo mutations in the patient and her parents. 
Based on the inheritance traits, we identified three 
heterozygous mutations, in which one was inherited 
from the father affecting Tenascin XB (TNXB) gene. 
However, this TNXB gene is not reported previously to 
be associated with VACTERL association. 
Interestingly, the patient inherited two heterozygous 
mutations affecting genes that are involved in the SHH 
pathway (Table 2 and Figure 2), i.e., KIF27 
(ENST00000297814: c.3004A>C:p.N1002H) and 
GNAS (ENST00000371098: c.205C>A:p.H69N) from 
her father and mother respectively, which were 
inherited via autosomal recessive trait. These 
mutations were predicted to be deleterious by SIFT, 
Polyphen-2, MutationTaster, FATHMM, CADD, 
PROVEAN or DANN. Other genetic mutations 
inherited from her father and mother are listed in 
Tables 3 and 4, respectively. 
 
Table 2. List of the homozygous and compound 
heterozygous mutations detected in this study. 
 
Descriptive summary of the selected homozygous, 
compound heterozygous and heterozygous mutations 
identified in the study. Homo, homozygous, CompHet, 

















Het CA CC CA 


















































Het GC GG GG 


















De novo mutations in VACTERL 
 
A total of 14 de novo mutations were identified in the 
patient (Table 2). Among them, one missense mutation 
was identified in the intraflagellar transport 140 
(IFT140) gene (ENST00000426508: 
c.683C>G:p.S228C), a homozygous mutation that was 
also predicted to be deleterious (Figure 2). Other de 
novo genetic mutations were also identified in the 
patient (Table 2). None of these genes are associated 
with VACTERL or VACTERL-like phenotypes 
 
Figure 2: Off-state of the sonic hedgehog signalling (SHH) 
pathway generated by PathCards database showing the 
interaction between the KIF7 (paralog to KIF27), GNAS and 
IFT140 (red arrow pointed). SHH pathway has been shown 
to be implicated in VACTERL and VACTERL-like 
association. 
 




Table 3. List of the other compound heterozygous and 
heterozygous mutations inherited from the father  
 
Descriptive summary of the identified other compound 
heterozygous and heterozygous mutations inherited from the 
father. CompHet, compound heterozygous, Het, 
heterozygous mutation. 
     
Mutation Mutation 
Type 
Patient Father Mother 
     
ADAMTS18: ENST00000449265:c.406 C > 
G:p.Q136E 
Het GC GC GG 
ADGRB1: ENST00000521208:c.3122 C > 
T:p.T1041M 
Het CT CT CC 




CG CG CC 




CT CT CC 
ANKRD12: ENST00000262126:c.1720 A > 
G:p.M574V 
Het AG AG AA 
ARHGEF28: ENST00000545377:c.4071 G 
>C:p.E1357D 
Het GC GC GG 
ASAP3: ENST00000336689:c.908 C > T:p.T303M Het GA GA GG 
BACH1: ENST00000399921:c.2033 c > G:p.A678G Het CG CG CC 
BAHD1: ENST00000561234:c.33 G > A:p.M11I Het GA GA GG 
BCKDHA: ENST00000540732:C.1262 G > 
A:p.R421H 
Het GA GA GG 
BIRC6: ENST00000421745:c.14494 A > 
G:p.T4832A 
Het AG AG AA 
BTN2A1: ENST00000312541:c.1406 G > 
A:p.R469K 
Het GA GA GG 
BTN2A2: ENST00000416795:c.1201 C > 
G:p.H401D 
Het CG CG CC 
BTN3A3: ENST00000339789:c.1154 C > 
T:p.P385L 
Het CT CT CC 
C6orf106: ENST00000374023:c.874 C > 
G:p.P292A 
Het GC GC GG 
CAPN5: ENST00000529629:c.349 T > G:p.Y117D Het TG TG TT 
CASP7: ENST00000369321:c.200 C > A:p.S67Y Het CA CA CC 
CD248: ENST00000311330:c.1235 C > G:p.P412R Het GC GC GG 
CDK11A/B: ENST00000479362:c.302 A > 
G:p.K101R 
Het TC TC TT 
CLEC1A:ENST00000414501:c.171 G > C:p.L57F Het CG CG CC 
CNTNAP2: ENST00000361727:c.3106 G > 
A:p.A1036T 
Het GA GA GG 
COA4: ENST00000537289:c.20 A > G:p.Q7R Het TC TC TT 
COL2A1: ENST00000380518:c.196 G > A:p.D66N Het CT CT CC 
COQ4: ENST00000609948:c.134 C > G:p.S45C Het CG CG CC 
CTNNAL1: ENST00000374595:c.983 G > 
A:p.R328H 
Het CT CT CC 
CXCL16: ENST00000574412:c.218 T > A:p.F73Y Het AT AT AA 
DAG1: ENST00000545947:c.220 G > A:p.V74I Het GA GA GG 
DBNDD2: ENST00000372723:c.455 A > 
G:p.D152G 
Het AG AG AA 
DCAF13: ENST00000519682:c.626 T > C:p.F209S Het TC TC TT 
DDX60L: ENST00000511577:c.2140 G > 
A:p.G714R 
Het CT CT CC 
DHRS1: ENST00000558340:c.22 C > T:p.Q8X Het GA GA GG 
DIEXF: ENST00000491415:c.1601 T > A:p.F534Y Het TA TA TT 
DNAH5: ENST00000265104:c.7452 C > 
A:p.F2484L 
Het GT GT GG 
DPCR1: ENST00000462446:c.869 G > A:p.G290E Het GA GA GG 
DUOXA1: ENST00000558422:c.77 G > A:p.S26N Het CT CT CC 
ELFN1: ENST00000424383:c.23 C > T:p.A8V Het CT CT CC 
EMC1: ENST00000477853:c.1862 G > A:p.R621H Het CT CT CC 
ESRRA: ENST00000468670:c.22 A > T:p.I8F Het AT AT AA 
FAM124A: ENST00000280057:c.1471 G > 
C:p.A491P 
Het GC GC GG 
FAT2: ENST00000261800:c.9805 C> T:p.R3269C Het GA GA GG 
FHOD1: ENST00000258201:c.3130 C > 
T:p.R1044W 
Het GA GA GG 
FKBP10: ENST00000489591:c.274 C > G:p.L92V Het CG CG CC 
FOXP1: ENST00000493089:c.160 G > A:p.A54T Het CT CT CC 
FXR1: ENST00000305586:c.1484 T > A:p.I495K Het TA TA TT 
GDPD5: ENST00000529721:c.1814 G > 
A:p.R605H 
Het CT CT CC 
GPATCH8: ENST00000434000:c.3934 G > 
A:p.A1312T 
Het CT CT CC 
HLAC: ENST00000383329:c.595 G > A:p.G199R Het CT CT CC 
HLADMA: ENST00000456800:c.708 C > 
A:p.H236Q 
Het GT GT GG 
HYDIN: ENST00000393567:c.13925 G > 
A:p.R4642H 
Het CT CT CC 
IGSF10: ENST00000282466:c.3104 G > 
C:p.R1035T 
Het CG CG CC 
IGSF9B: ENST00000533871:c.3530 C > 
T:p.P1177L 
Het GA GA GG 
IRX6: ENST00000290552:c.1147 G > C:p.G383R Het GC GC GG 
ISM1: ENST00000262487:c.476 G > A:p.R159Q Het GA GA GG 
KAZN: ENST00000376030:c.1566 G > T:p.E522D Het GT GT GG 
KDM3B: ENST00000314358:c.3604 A > 
C:p.N1202H 
Het AC AC AA 
KIAA1614: ENST00000367588:c.3455 A > 
T:p.N1152I 
Het AT AT AA 
KLB: ENST00000257408:c.2491 G > T:p.V831L Het GT GT GG 
KMT2D: ENST00000301067:c.10009 C > 
A:p.H3337N 
Het GT GT GG 
LAG3: ENST00000203629:c.1333 C > T:p.L445F Het CT CT CC 
LAMA3: ENST00000399516:c.2402 G > 
T:p.G801V 
Het GT GT GG 
LDAH: ENST00000440866:c.272 A > T:p.D91V Het TA TA TT 
LGI3: ENST00000517694:c.604 T > C:p.Y202H Het AG AG AA 
LOC81691: ENST00000568894:c.133 G > 
A:p.A45T 
Het GA GA GG 
LRFN1: ENST00000248668:c.1051 G > C:p.G351R Het CG CG CC 
LRRC43: ENST00000425921:c.1119 C > 
G:p.D373E 
Het CG CG CC 
MAST4: ENST00000404260:c.5840 A > 
C:p.N1947T 
Het AC AC AA 
MCM3AP: ENST00000397708:c.507 C > 
A:p.S169R 
Het GT GT GG 
MRPS5: ENST00000272418:c.1157 C > T:p.S386F Het GA GA GG 
MS4A63: ENST00000532756:c.106 G > C:p.A36P Het GC GC GG 
MTFMT: ENST00000560717:c.44 G > C:p.G15A Het CG CG CC 
NBEAL1: ENST00000449802:c.1211 C > T:p.T404I Het CT CT CC 
NLRP12: ENST00000535162:c.629 C > T:p.P210L Het GA GA GG 
NRN1L: ENST00000339176:c.32 G > C:p.C11S Het GC GC GG 
NUP85: ENST00000245544:c.1823 C > T:p.T608M Het CT CT CC 
OR5B2: ENST00000302581:c.319 A > G:p.T107A Het TC TC TT 




PCDHA: ENST00000532602:c.A2713 A > 
G:p.N905D 
Het AG AG AA 
PCDHA6: ENST00000529310:c.2027 C > 
T:p.P676L 
Het CT CT CC 
PEX16: ENST00000378750c.187 G > A:p.G63R Het CT CT CC 
PKHD1L1: ENST00000378402:c.2867 C > 
A:p.A956D 
Het CA CA CC 
PLCE1: ENST00000260766:c.6691 T > 
C:p.F2231L 
Het TC TC TT 
PLEKHA5: ENST00000429027:c.2077 A > 
G:p.M693V 
Het AG AG AA 
PLEKHG3: ENST00000394691:c.1337 G > 
A:p.R446Q 
Het GA GA GG 
PON3: ENST00000451904:c.289 G > A:p.A97T Het CT CT CC 
PRRC2A: ENST00000376033:c.4316 G > 
A:p.R1439Q 
Het GA GA GG 
PRUNE2: ENST00000428286:c.2438 T > 
C:p.L813P 
Het AG AG AA 
PYGM: ENST00000164139:c.2290 A > G:p.N764D Het TC TC TT 
RAB3GAP2: ENST00000358951:c.1660 A > 
G:p.M554V 
Het TC TC TT 
RAD52: ENST00000541619:c.34 C > T:p.R12C Het GA GA GG 
RASL10A: ENST00000401450:c.208 G > A:p.G70R Het CT CT CC 
RBFOX2: ENST00000438146:c.473 G > 
T:p.G158V 
Het CA CA CC 
RBM47: ENST00000515053:c.366 C > G:p.H122Q Het GC GC GG 
REP15: ENST00000310791:c.624 T > G:p.C208W Het TG TG TT 
RRAGA: ENST00000380527:c.702 C > G:p.I234M Het CG CG CC 
SAG: ENST00000409110:c.1159 C > A:p.L387M Het CA CA CC 
SCNN1D: ENST00000379116:c.661 C > 
T:p.R221W 
Het CT CT CC 
SEMA5A: ENST00000382496:c.1568 C > 
T:p.T523M 
Het GA GA GG 
SFTPA1: ENST00000419470:c.698 G > T:p.G233V Het GT GT GG 
SH3BP2: ENST00000511747:c.914 C > T:p.P305L Het CT CT CC 
SKIV2L2: ENST00000230640:c.2102 G > 
A:p.R701H 
Het GA GA GG 
SLC20A2: ENST00000520262:c.787 G > A:p.V263I Het CT CT CC 
SOGA1: ENST00000357779:c.3214 C > 
T:p.R1072W 
Het GA GA GG 
SPANXC/D:ENST00000370515:exon2:c.G253A:p.
E85K 
Het CT CT CC 
SPIDR: ENST00000518074:c.1574 G > A:p.R525H Het GA GA GG 
SPZ1: ENST00000296739:c.1000 A > G:p.R334G Het AG AG AA 
SSFA2: ENST00000431877:c.673 C > G:p.Q225E Het CG CG CC 
ST6GALNAC4: ENST00000335791:c.491 G > 
A:p.R164H 
Het CT CT CC 
STRIP2: ENST00000435494:c.367 C > T:p.R123W Het CT CT CC 
SYNGR1: ENST00000381535:c.62 A > G:p.Q21R Het AG AG AA 
TAF1L: ENST00000242310:c.944 A > G:p.Y315C Het TC TC TT 
TKTL2: ENST00000280605:c.70 C > T:p.R24W Het GA GA GG 
TMPRSS9: ENST00000332578:c.3020 G > 
A:p.G1007D 
Het GA GA GG 
TPRKB: ENST00000409716:c.362 A > G:p.N121S Het TC TT TC 
TRIM47: ENST00000587339:c.115 G > A:p.A39T Het CT CT CC 
TSSC4: ENST00000437110:c.151 C > A:p.P51T Het CA CA CC 
TTC7A: ENST00000409245:c.335 G > A:p.R112Q Het GA GA GG 
USP17L2: ENST00000333796:c.1238 C > 
T:p.P413L 
Het GA GA GG 
USP42: ENST00000306177:c.1660 C > A:p.P554T Het CA CA CC 
WASF1: ENST00000392589:c.1048 C > T:p.P350S Het AA AA GG 
WDPCP: ENST00000409562:c.1310 G > T:p.S437I Het CA CA CC 
ZNF573: ENST00000339503:c.475 A > G:p.T159A Het TC TC TT 
ZNF740: ENST00000416904:c.550 T > G:p.S184A Het TG TG TT 
ZNF766: ENST00000439461:c.1351 A > 
C:p.S451R 
Het AC AC AA 
ZNF865: ENST00000568956:c.2297 G > 
T:p.G766V 
Het GT GT GG 
     





Table 4. List of the other compound heterozygous and 
heterozygous mutations inherited from the mother 
 
Descriptive summary of the identified other compound 
heterozygous and heterozygous mutations inherited from the 
mother. Homo, homozygous, CompHet, compound 
heterozygous, Het, heterozygous mutation. 
 
     
Mutation Mutation 
Type 
Patient Father Mother 
     
ABCA7: ENST00000263094:c.1193 G > 
A:p.G398D 
Het GA GG GA 
ADAMTS7: ENST00000388820:c.2731 G > 
A:p.V911M 











Het AG AA AG 
AMZ1: ENST00000312371:c.1226 G > A:p.R409Q Het GA GG GA 
ARRB2: ENST00000575877:c.788 G > A:p.R263H Het GA GG GA 
BCL7A: ENST00000538010:c.428 C > T:p.P143L Het CT CC CT 
C8orf34A: ENST00000512294:c.76 G > A:p.G26R Het CT CC CT 
CACNA1G: ENST00000416767:c.4630 G > 
A:p.V1544I 
Het GA GG GA 
CANT1: ENST00000591773:c.205 C > T:p.P69S Homo AA GG AA 
CARD6: ENST00000254691:c.943 T > C:p.C315R Het TC TT TC 
CCDC102E: ENST00000584775:c.220 C > 
T:p.R74C 
Het CT CC CT 
CD163L1: ENST00000416109:c.1828 T > 
C:p.F610L 
Het AG AA AG 
CDY1: ENST00000328908:c.887 A > G:p.N296S Het AG AA AG 
CERS4: ENST00000558331:c.791 T > G:p.L264R Het TG TT TG 
CES2: ENST00000417689:c.343 G > A:p.A115T Het GA GG GA 




GA GG GA 




GA GG GA 
CHPF2: ENST00000495645:c.341 G > T:p.R114L Het GT GG GT 
COLQ: ENST00000603808:c.476 G > C:p.G159A Het CG CC CG 
CPAMD8: ENST00000443236:c.4402 G > 
A:p.V1468M 
Het CT CC CT 
CTNNA3: ENST00000433211:c.1231 A > 
G:p.I411V 
Het TC TT TC 
CUBN: ENST00000377833:c.10215 C> 
A:p.N3405K 
Het GT GG GT 
DAGLA: ENST00000257215:c.2210 C > T:p.S737L Het CT CC CT 
DDOST: ENST00000602624:c.815 A > G:p.Y272C Het TC TT TC 
DNAH10: ENST00000409039:c.4897 G > 
A:p.A1633T 
Het GA GG GA 
EGLN1: ENST00000366641:c.832 G > A:p.D278N Het CT CC CT 
ENTPD7: ENST00000370489:c.1541 C > 
T:p.T514M 
Het CT CC CT 
ERP29: ENST00000261735:c.205 A > C:p.K69Q Het AC AA AC 
FCAMR: ENST00000400962:c.445 A > G:p.R149G Het TC TT TC 
FCMR: ENST00000367091:c.1128 G > C:p.M376I Het CG CC CG 
FFAR2: ENST00000599180:c.299 T > C:p.L100P Het TC TT TC 
GAL: ENST00000265643:c.178 C > T:p.L60F Het CT CC CT 
GAPVD1: ENST00000495955:c.2102 C > 
T:p.P701L 
Het CT CC CT 
GLIS1: ENST00000312233:c.172 C > T:p.P58S Het GA GG GA 
GPR37L1: ENST00000367282:c.194 C > T:p.A65V Het CT CC CT 
HIST3H3: ENST00000366696:c.47 C > T:p.A16V Het GA GG GA 
HIVEP1: ENST00000379388:c.5858 T > 
C:p.L1953S 
Het TC TT TC 
IRS2: ENST00000375856:c.2657 G > T:p.R886L Het CA CC CA 
ITGA11: ENST00000423218:c.2654 A > 
G:p.E885G 
Het TC TT TC 
KIAA2026: ENST00000399933:c.1517 G > 
A:p.R506Q 
Het CT CC CT 
KIR2DL3: ENST00000434419:c.197 T > A:p.F66Y Het TA TT TA 
KLHL14: ENST00000359358:c.961 A > G:p.K321E Het TC TT TC 
KLHL42: ENST00000539176:c.958 G > A:p.E320K Het GA GG GA 
KRT6A: ENST00000330722:c.701 G > A:p.R234H Het CT CC CT 
KRTAP5-1: ENST00000382171:c.656 G > 
A:p.S219N 
Het CT CC CT 
LIMCH1: ENST00000513024:c.20 A > G:p.D7G Het AG AA AG 
LINC01619: ENST00000549802:c.187 G > 
A:p.V63M 
Het CT CC CT 
LRRIQ4: ENST00000340806:c.223 G > T:p.V75F Het GT GG GT 
MAP2: ENST00000360351:c.4912 G > 
A:p.V1638M 
Het GA GG GA 
MARK3: ENST00000416682:c.1729 C > T:p.R577C Het CT CC CT 




GA GG GA 




AG AA AG 




CT CC CT 




CT CC CT 




CT CC CT 
MUC22: ENST00000561890:c.4840 G > 
A:p.V1614I 
Het GA GG GA 
MUM1: ENST00000344663:c.869 C > G:p.S290W Het CG CC CG 
MYOM3: ENST00000374434:c.1232 G > 
A:p.R411Q 
Het CT CC CT 
NDUFS8: ENST00000453471:c.4 C > T:p.R2C Het CT CC CT 
NEUROD1: ENST00000295108:c.751 G > 
T:p.A251S 
Het CA CC CA 
NEXN: ENST00000334785:c.512 T > C:p.I171T Het TC TT TC 
NFATC1: ENST00000592223:c.815 C > T:p.P272L Het CT CC CT 
NKAPL: ENST00000343684:c.176 A > C:p.D59A Het AC AA AC 
NLRP7: ENST00000588756:c.251 G > A:p.C84Y Het CT CC CT 
OBSCN: ENST00000570156:c.20155 G > 
A:p.D6719N 
Het GA GG GA 
OR4K2: ENST00000298642:c.451 A > G:p.M151V Het AG AA AG 
PCDHA4: ENST00000530339:c.214 G > C:p.G72R Comp 
Het 
GC GG GC 
PCDHA4: ENST00000530339:c.218 G > A:p.G73D Comp 
Het 
GA GG GA 
PCDHGA10: ENST00000398610:c.1897 G > 
A:p.A633T 
Het GA GG GA 
PCDHGA11: ENST00000518882:c.1382 A > 
G:p.Y461C 
Het AG AA AG 
PCM1: ENST00000519253:c.3520 A > 
G:p.T1174A 
Het AG AA AG 
PDCD4: ENST00000393104:c.502 G > A:p.G168R Het GA GG GA 
PEX26: ENST00000329627:c.427 G > A:p.A143T Het GA GG GA 
PHLPP1: ENST00000262719:c.1184 G > 
T:p.R395L 
Het GT GG GT 
PIGV: ENST00000449950:c.499 C > G:p.L167V Het CG CC CG 
PKD1: ENST00000423118:c.8611 G > A:p.A2871T Het CT CC CT 
PKHD1: ENST00000371117:c.5959 G > 
A:p.A1987T 
Het CT CC CT 
PLEKHA4: ENST00000263265:c.1712 G > 
A:p.R571H 
Het CT CC CT 
PLEKHG1: ENST00000367328:c.2329 T > 
G:p.C777G 
Het TG TT TG 
PREX1: ENST00000396220:c.1169 A > T:p.E390V Het TA TT TA 
PRSS3: ENST00000457896:c.194 T > A:p.I65N Comp 
Het 
TA TT TA 
PRSS3: ENST00000457896:c.198 C > G:p.S66R Comp 
Het 
CG CC CG 
PRSS3: ENST00000457896:c.202 C > T:p.Q68X Comp 
Het 
CT CC CT 
PRX: ENST00000324001:c.641 C > G:p.P214R Het GC GG GC 
PTPN13: ENST00000436978:c.5018 C > 
A:p.A1673E 
Het CA CC CA 
RHAG: ENST00000371175:c.64 T > G:p.L22V Het AC AA AC 
RHBDF2: ENST00000592123:c.325 C > 
T:p.R109C 
Het GA GG GA 
RPL13: ENST00000452368:c.359 G > A:p.R120Q Het GA GG GA 
RPL13A: ENST00000391857:c.302 G > A:p.R101H Het GA GG GA 
RPL3L: ENST00000268661:c.745 C > T:p.R249C Het GA GG GA 
RPTN: ENST00000316073:c.460 A > G:p.R154G Het TC TT TC 
RSPO1: ENST00000401068:c.512 G > C:p.G171A Het CG CC CG 
SAP18: ENST00000450573:c.16 G > A:p.A6T Het GA GG GA 
SGK494: ENST00000584196:c.188 A > G:p.Y63C Het CC TT CC 
SIM2: ENST00000430056:c.232 A > G:p.K78E Het AG AA AG 
SLC24A4: ENST00000531433:c.502 G > A:p.V168I Het GA GG GA 
SLC25A15: ENST00000338625:c.147 C > 
G:p.D49E 
Het CG CC CG 
SP100: ENST00000264052:c.2242 G > A:p.E748K Het GA GG GA 
SPHK2: ENST00000600537:c.793 G > T:p.A265S Het GT GG GT 
SSC5D: ENST00000587166:c.2116 C > T:p.R706X Het CT CC CT 
SVEP1: ENST00000401783:c.5595 T > G:p.F1865L Het AC AA AC 
TAS2R42: ENST00000334266:c.694 G > 
A:p.A232T 
Het CT CC CT 
TEKT5: ENST00000283025:c.640 C > T:p.L214F Het GA GG GA 
TEX15: ENST00000256246:c.6874 A > 
G:p.T2292A 
Het TC TT TC 
THEMIS: ENST00000368250:c.1019 A > 
T:p.K340M 
Het TA TT TA 
THSD4: ENST00000355327:c.1064 G > A:p.R355H Het GA GG GA 
TMEM176A: ENST00000484928:c.455 G > 
A:p.R152H 
Het GA GG GA 
TMEM219: ENST00000561899:c.688 C > 
T:p.R230C 
Het CT CC CT 
TMEM74: ENST00000297459:c.164 T > C:p.M55T Het AG AA AG 
TNKS1BP1: ENST00000528882:c.11 C > G:p.S4C Het GC GG GC 
TONSL: ENST00000409379:c.3347 G > 
A:p.R1116H 
Het CT CC CT 
TOR2A: ENST00000458505:c.98 T > C:p.L33P Het AG AA AG 
TPR: ENST00000367478:c.5770 C > G:p.Q1924E Het GC GG GC 
TRANK1: ENST00000429976:c.2324 C > 
T:p.T775M 
Het GA GG GA 
UBASH3B: ENST00000284273:c.1049 G > 
A:p.R350Q 
Het GA GG GA 
USP35: ENST00000529308:c.2351 C > T:p.S784L Het CT CC CT 
ZC3HAV1: ENST00000464606:c.3046 A > 
G:p.T1016A 
Het TC TT TC 
ZPBP: ENST00000419417:c.346 G > A:p.A116T Het CT CC CT 













In the present study, we have identified several 
possible mutations that may contribute to the 
VACTERL association in an infant girl. These 
included two inherited heterozygous mutations in 
KIF27 and GNAS genes, as well as the one de novo 
missense mutation of the IFT140 gene, in which these 
affected genes are involved in the SHH pathway. 
KIF27 and GNAS gene mutations are inherited via the 
autosomal recessive pattern. From the trio WES 
analysis, we identified a mutation of the KIF27 gene 
(ENST00000297814: c.3004A>C:p.N1002H) which 
is inherited from the father, and a mutation in the 
GNAS gene (ENST00000371098: c.205C>A:p.H69N) 
which is inherited from the mother. These mutations 
could be causative of the VACTERL association seen 
in the patient. To the best of our knowledge, we are the 
first to describe these two genetic mutations in 
association with the VACTERL phenotype. Currently, 
the genetic aetiology of VACTERL association is not 
well described as its phenotypes are too heterogeneous 
[1]. Thus, until now, there is no specific genetic 
marker to diagnose VACTERL association and also to 
help identify the carriers. Therefore, our findings of 
these possible genetic mutations in our Malaysian 
infant girl diagnosed with VACTERL association may 
provide a better understanding of the genetic 
architecture of VACTERL phenotypes and hence may 
offer the information needed for familial screening of 
VACTERL carriers and genetic counselling.  
 
Two digenic inherited heterozygous mutations in our 
VACTERL patient are involved in SHH signalling. 
KIF27 is a member of the kinesin 4 superfamily, and 
its paralog protein is KIF7 [30]. Although no specific 
function was identified for KIF27 protein in 
VACTERL pathogenesis, both of KIF27 and KIF7 
proteins are needed to fulfil the same role of a single 
Drosophila melanogaster of kinesin-like protein 
Costal-2 (Cos2); which is an important negative 
regulator in SHH signalling [30]. SHH signalling has 
been implicated as the key signal in developmental 
biology particularly in regulating the ventral neural 
tube, the anterior–posterior limb axis and the ventral 
somites formation [31]. Mice knockout of the SHH 
gene and the transcription factor, GLI genes, resulted 
in mutant mice that exhibited the similar VACTERL 
phenotypes [32]. Thus, suggesting the possible genetic 
and molecular pathogenesis of VACTERL association 
via KIF27 mutation and SHH signalling. As for GNAS 
gene that encodes the α-subunit of the heterotrimeric 
stimulatory G protein (Gsα), this GNAS protein is 
responsible for molecular switching of the various 
peptide hormones binding the G-protein-coupled 
receptors (GPCR) [33]. Interestingly, a knockout mice 
study of gain- and loss-of-function of the GNAS gene 
revealed that Gsα protein inhibits SHH signalling via 
the cAMP-dependent pathway to regulate GLI3 
processing and GLI2 activation [34]. Therefore, these 
findings may imply that any mutation in the GNAS 
gene can contribute to VACTERL and VACTERL-
like phenotype via interacting with SHH signalling. 
However, to what extent these heterozygous inherited 
mutations in KIF27 and GNAS genes in our patient 
caused the VACTERL or VACTERL-like phenotypes 
is unknown and would require more functional studies 
to evaluate the impact of the mutations in SHH and 
VACTERL development. 
 
In the present study, we also identified a homozygous, 
de novo mutation that may also be associated with 
VACTERL or VACTERL-like association via SHH 
signalling. A missense mutation in the IFT140 gene 
(ENST00000426508: c.683C>G:p.S228C) was 
identified in our patient. IFT140 gene encodes a 
subunit of intraflagellar transport A (IFTA) complex 
that is responsible for the movement of molecules 
from the axon to the cell body or known as the 
retrograde transport in primary cilia [35]. Mutations in 
the genes that encode the components of IFTA 
complex can affect the skeleton development and 
maintenance [36], thus suggesting that IFTA complex 
play a role in VACTERL pathogenesis. Mutant mice 
that lacked IFTA complex expression showed a loss of 
SHH activity with severe disruptions of the cilia 
structure and membrane protein trafficking [37]. 
Another study of mutant mice with low expression of 
IFT172 gene (another component of IFT) also showed 
that these mice developed VACTERL and 
VACTERL-like phenotypes (12), due to dysregulation 
of GLI activation and repression [13, 38]. However, 
how this de novo mutation in IFT140 gene can cause 
VACTERL or VACTERL-like phenotypes in our 
patient is unknown and whether the mechanisms of 
IFT140 dysregulation contributing to the VACTERL 
phenotypes are similar to the IFT172 mode of action 
also needs further confirmation.  
 
Our present study has a few limitations that needed to 
be addressed. One is that we cannot conclude that the 
three genetic mutations in association with VACTERL 
phenotypes were causative mutations. Functional 
studies will be required to identify which of those 
mutations (KIF27, GNAS and IFT140) contribute to 
the pathogenesis of VACTERL. We were also not able 
to validate the findings with other VACTERL subjects 
and using other sequencing platforms. This is 
particularly important as there are many possible 
technical challenges in WES analysis to discover 
accurate and true genetic mutations (false positive), 
and also to apply such mutations in the biologically 




meaningful information or disease pathogenesis [39]. 
However, many other studies did show that the WES 
technique has high sensitivity in detecting true genetic 
variants and also has high replicability across different 
platforms [40], which suggests that the WES findings 
in this study warrant further investigation in 
VACTERL pathogenesis. Furthermore, the patient’s 
mother has a history of diabetes mellitus, which is a 
risk factor for the development of VACTERL in the 
offspring [41, 42]. The exact mechanism of how 
diabetes mellitus contributes to the congenital 
malformations is unknown, though hyperglycemia, 
oxidative stress and mitochondrial dysfunction are 
thought to play a role in disturbing the certain key 
developmental pathways in the foetus [14, 42]. Even 
so, no strong evidence is reported to show a causal 
relationship between maternal diabetes and 
VACTERL development in these infants, as many of 
the VACTERL infants are not born to women with 
diabetes [42, 43]. Despite these limitations, the fact 
that those three genetic mutations in KIF27, GNAS and 
IFT140 genes are associated with SHH signalling have 
provided additional knowledge and also the additional 
candidate genes involved in the pathogenesis of 




In the present study, we performed the trio-genetic 
analysis to discover the mutations of VACTERL 
association in our Malaysian infant patient together 
with her parents using the WES technique. We 
identified three mutations in KIF27, GNAS and 
IFT140 genes that may be responsible for the 
VACTERL association, possibly via a disruption in 
SHH pathway. We also identified a de novo missense 
mutation in the IFT140 gene which may also 
contribute to the molecular pathogenesis of 
VACTERL in our patient. This is the first time that 
these three genetic mutations are reported in 
association with VACTERL and VACTERL-like 
phenotypes. The identification of these genetic 
mutations may offer new knowledge for future studies 
to understand the molecular mechanisms for 
VACTERL pathogenesis and potentially to improve 
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